Concepedia

Michel De Cleyn

MD

Statistics

Publications

6

Citations

232

H-Index

6

Active since

2012

Affiliations

Janssen (Belgium)(Current)

Janssen (United States)

Springhouse

Michel De Cleyn is an author at Janssen (Belgium) specializing in pharmacology, medicinal chemistry, and enzyme inhibition.

Publications per year

2012–2021

6

Publications

6

1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads

Frederik Rombouts, Gary Tresadern, Óscar Delgado et al. · Journal of Medicinal Chemistry · 2015 · 79 citations · Full text

, , +17

Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators

François Bischoff, Didier Berthelot, Michel De Cleyn et al. · Journal of Medicinal Chemistry · 2012 · 60 citations · Full text

, , +13

Evaluation of a Series of β-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads

Daniel Oehlrich, Aldo Peschiulli, Gary Tresadern et al. · ACS Medicinal Chemistry Letters · 2019 · 38 citations · Full text

, , +17

JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate

Frederik Rombouts, Ken‐ichi Kusakabe, Richard Alexander et al. · Journal of Medicinal Chemistry · 2021 · 21 citations · Full text

, , +14

Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate

Harrie J. M. Gijsen, Sergio A. Alonso de Diego, Michel De Cleyn et al. · Journal of Medicinal Chemistry · 2018 · 18 citations · Full text

, , +8

1–5 of 6